Characteristic | All patients | < 80 years | ≥80 years | p-value* |
---|---|---|---|---|
Full cohort | ||||
Number of patients | 17,464 | 14,824 (84.9%) | 2640 (15.1%) | |
Patient days | 76,424 | 67,480 | 8944 | |
Length of stay (median, IQR (days)) | 0.9 (0.8–2.6) | 0.9 (0.8–2.7) | 0.9 (0.8–2.0) | 0.0004 |
Female patients | 7498 (42.9%) | 5875 (39.6%) | 1623 (61.5%) | < 0.0001 |
ICU mortality rate | 1448 (8.3%) | 1136 (7.7%) | 312 (11.8%) | < 0.0001 |
SAPS II (median of means, IQR)a | 20.1 (13.3–28.9) | 19.9 (13.0–28.6) | 22.0 (15.0–30.0) | < 0.0001 |
TISS-10 (median of means, IQR) | 9.7 (5.0–12.5) | 10.0 (5.7–12.6) | 7.5 (5.0–11.1) | < 0.0001 |
Patients treated with antibacterials | ||||
Number of patients | 5785 (33.1%b) | 5060 (34.1%c) | 725 (27.5%c) | < 0.0001 |
Patient days | 44,936 | 40,831 | 4105 | |
Length of stay (median, IQR (days)) | 2.2 (0.9–8.7) | 2.3 (0.9–9.1) | 2.0 (0.9–5.7) | 0.0142 |
Female patients | 2047 (35.4%) | 1689 (33.4%) | 358 (49.4%) | < 0.0001 |
ICU mortality rate | 869 (15.0%) | 726 (14.4%) | 143 (19.7%) | 0.0002 |
SAPS II (median of means, IQR)a | 24.6 (17.5–32.7) | 24.4 (17.3–33.0) | 25.8 (18.5–31.5) | 0.4291 |
TISS-10 (median of means, IQR) | 10.7 (7.5–14.1) | 10.8 (7.8–14.4) | 9.0 (5.0–12.1) | < 0.0001 |
Exposed patient days | 29,578 | 26,808 | 2770 | |
Number of Antibacterial prescriptions | 190,689 | 172,963 | 17,726 | |
Therapy days | 52,342 | 47,630 | 4712 |